Article
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Feb 2010
Khambata-Ford Shirin, Harbison Christopher T, Hart Lowell L, Awad Melissa, Xu Li-An, Horak Christine E, Dakhil Shaker, Hermann Robert C, Lynch Thomas J, Weber Martin R
Abstract excerpt
PURPOSE The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is efficacious in multiple tumor types. Patient selection with markers predictive of benefit may enhance its therapeutic index. This retrospective, correlative analysis of the phase III trial BMS099 of cetuximab in advanced non-small-cell lung cancer (NSCLC) was conducted to identify molecular markers for the selection of patients most...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.